Philip Bergin

Philip Bergin

Auto-generated profile, based on publicly available information

Philip Bergin

International AIDS Vaccine Initiative Human Immunology Laboratory, Faculty of Medicine, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAloysius Ssemaganda
Aloysius Ssemaganda
LKLindsay Kindinger
Lindsay Kindinger
PBPhilip Bergin
Philip Bergin
LNLeslie Nielsen
Leslie Nielsen
JMJuliet Mpendo
Juliet Mpendo
IMIngrid Müller
Ingrid Müller
We have previously shown that in successful pregnancies increased arginase activity is a mechanism that contributes to the suppression of the maternal immune system. We identified the main type of arginase-expressing cells as a population of activated low-density granulocytes (LDGs) in peripheral blood mononuclear cells and in term placentae. In the present study, we analyzed the phenotype of LDGs and compared it to the phenotype of normal density granulocytes (NDGs) in maternal peripheral blood, placental biopsies and cord blood. Our data reveal that only LDGs but no NDGs could be detected in placental biopsies. Phenotypically, NDGs and LDGs from both maternal and cord blood expressed different levels of maturation, activation and degranulation markers. NDGs from the maternal and cord blood were phenotypically similar, while maternal, cord and placental LDGs showed different expression levels of CD66b. LDGs present in cord blood expressed higher levels of arginase compared to maternal and placental LDGs. In summary, our results show that in maternal and cord blood, two phenotypically different populations of neutrophils can be identified, whereas in term placentae, only activated neutrophils are present.

21 September 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WJWalter Jaoko
Walter Jaoko
EKEtienne Karita
Etienne Karita
KKKayitesi Kayitenkore
Kayitesi Kayitenkore
GOGloria Omosa-Manyonyi
Gloria Omosa-Manyonyi
SASusan Allen
Susan Allen
JBJob Bwayo
Job Bwayo
We conducted a double-blind, randomized, placebo-controlled Phase I study of a recombinant replication-defective adenovirus type 5 (rAd5) vector expressing HIV-1 Gag and Pol from subtype B and Env from subtypes A, B and C, given alone or as boost following a DNA plasmid vaccine expressing the same HIV-1 proteins plus Nef, in 114 healthy HIV-uninfected African adults. Volunteers were randomized to 4 groups receiving the rAd5 vaccine intramuscularly at dosage levels of 1×1010 or 1×1011 particle units (PU) either alone or as boost following 3 injections of the DNA vaccine given at 4 mg/dose intramuscularly by needle-free injection using Biojector® 2000. Safety and immunogenicity were evaluated for 12 months. Both vaccines were well-tolerated. Overall, 62% and 86% of vaccine recipients in the rAd5 alone and DNA prime - rAd5 boost groups, respectively, responded to the HIV-1 proteins by an interferon-gamma (IFN-γ) ELISPOT. The frequency of immune responses was independent of rAd5 dosage levels. The highest frequency of responses after rAd5 alone was detected at 6 weeks; after DNA prime - rAd5 boost, at 6 months (end of study). At baseline, neutralizing antibodies against Ad5 were present in 81% of volunteers; the distribution was similar across the 4 groups. Pre-existing immunity to Ad5 did not appear to have a significant impact on reactogenicity or immune response rates to HIV antigens by IFN-γ ELISPOT. Binding antibodies against Env were detected in up to 100% recipients of DNA prime - rAd5 boost. One volunteer acquired HIV infection after the study ended, two years after receipt of rAd5 alone. The HIV-1 rAd5 vaccine, either alone or as a boost following HIV-1 DNA vaccine, was well-tolerated and immunogenic in African adults. DNA priming increased the frequency and magnitude of cellular and humoral immune responses, but there was no effect of rAd5 dosage on immunogenicity endpoints. ClinicalTrials.gov NCT00124007

1 January 2004 in Microbes and Infection
Verified
Journal Article
Closed access
MVMargareta Verdrengh
Margareta Verdrengh
LCL.VIncent Collins
L.VIncent Collins
PBPhilip Bergin
Philip Bergin
ATAndrej Tarkowski
Andrej Tarkowski

24 May 2004 in Helicobacter
Verified
Journal Article
Closed access
PDF file
PBPhilip J Bergin
Philip J Bergin
EAEdebo Anders
Edebo Anders
WSWen Sicheng
Wen Sicheng
JEJohnsson Erik
Johnsson Erik
AJAndersson Jennie
Andersson Jennie
QMQuiding‐Järbrink Marianne
Quiding‐Järbrink Marianne

1 March 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ASAggeliki Spentzou
Aggeliki Spentzou
PBPhilip Bergin
Philip Bergin
DGDilbinder Gill
Dilbinder Gill
HCHannah M Cheeseman
Hannah M Cheeseman
AAAmbreen Ashraf
Ambreen Ashraf
PHPeter Hayes
Peter Hayes
We have characterized an assay measuring CD8 T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating speci

9 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TCTom Cloke
Tom Cloke
MMMarkus Munder
Markus Munder
PBPhilip Bergin
Philip Bergin
SHShanthi Herath
Shanthi Herath
MMManuel Modolell
Manuel Modolell
PKPascale Kropf
Pascale Kropf
We have recently identified a novel population of activated low-density granulocytes (LDGs) in peripheral blood mononuclear cells of HIV seropositive patients. LDGs have a similar morphology to normal density granulocytes (NDGs), but are phenotypically different. Here we measured the expression levels of different phenotypic markers of granulocytes in the blood of HIV seropositive patients at different stages of HIV infection to determine whether the phenotype of NDGs and LDGs are affected by disease severity. Our results reveal that the phenotype of NDGs, but not that of LDGs, varies according to the severity of the disease.